Material Transfer Agreements (MTA)

The terms in a Material Transfer Agreement (MTA) define the permitted use of materials for non-commercial research only, for a specific research project, and not for use with humans. MTA terms protect the research interests of the providing scientist, as well as protecting the providing institution from any liability that might arise from the recipient's use of the materials.

Procedure for MTAs

You must have a fully executed MTA before you can send or receive materials to/or from a third party. 

If you are the providing scientist, you can initiate the process by completing an outgoing MTA Request form.

  • UB will prepare the MTA when it receives your completed form. 
  • UB may contact you with questions when preparing and negotiating the MTA.
  • UB will notify you when it is executed so that you may transfer the requested materials to the recipient.

If the recipient/sender is another nonprofit institution, you can expedite the process by using a Uniform Biological Material Transfer Agreement (UBMTA) implementing letter or a simple letter agreement for the transfer of research materials.

  • UB will decide based on your completed request form.
  • If the recipient/sender is a commercial entity, the preparation and negotiation of an MTA is more complex and often takes longer to finalize.
  • If you are the receiving scientist, you can contact UB by submitting the Incoming MTA Request form.
Material Transfer Agreements (MTA)

Researchers will need a Material Transfer Agreement before sending or receiving materials from a third party.

Request an MTA form.

Kerafast Blanket MTA


UB has partnered with Kerafast, a company that commercializes unique consumable laboratory reagents developed in UB labs such as: plasmids, antibodies, cell lines, toxins, peptides, viruses, and enzymes.

Advantages of the the Kerafast Blanket MTA

Kerafast has a blanket MTA with UB and can streamline the marketing and distribution of unique lab reagents. Kerafast will set up a web page for the product, as well as for the investigator. Additionally, Kerafast will advertise the product, send targeted e-mails, and deal with customer service interactions to distribute the reagents worldwide. In return, the PI receives a percentage of the profit as a royalty payment every quarter. The agreement is non-exclusive so that one can still share reagents freely with other investigators.

If you are interested in more details, please contact the UB Kerafast representative:

Confidential Disclosure Agreements (CDA)

Confidential Disclosure Agreements (CDA) preserve intellectual property protections, allowing the exchange of secret or proprietary information in negotiating future sponsored research agreements, clinical trial agreements, research collaborations or license agreements.

When we receive your initial request, we will assign your CDA for review and, if necessary, begin negotiation. We may contact you with follow-up questions.

Confidential Disclosure Agreements (CDA)

Confidential Disclosure Agreements (CDA) help protect your intellectual property and proprietary information.

Request a CDA form.

Industry Sponsored Research

If you are discussing collaborations or sponsored research with a company, please first contact Sponsored Project Services (SPS) to begin developing the scope of work, budget and contract.

SBIR / STTR Funding Opportunities

Most federal agencies are required to allocate a portion of their funding to Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants. Both programs require a company to be the applicant. This provides an opportunity for researchers to either collaborate with an established company or consider starting a company.